Vaccinex Q1 EPS $(2.94), Sales $104.00K Down From $550.00K YoY
Portfolio Pulse from Benzinga Newsdesk
Vaccinex (NASDAQ:VCNX) reported a Q1 EPS of $(2.94) and sales of $104.00K, down 81.09% from $550.00K YoY.
May 15, 2024 | 10:14 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Vaccinex reported a significant decline in both EPS and sales for Q1. EPS was $(2.94) and sales were $104.00K, an 81.09% decrease YoY.
The significant decline in both EPS and sales indicates poor financial performance, likely leading to a negative short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100